Company intelligence / Profile preview
Epix Pharmaceuticals
Lexington, Massachusetts, United Statesepixpharma.com ↗
- Ownership
- Private
- Employees
- ~28
- Development stage
- Phase 2
01
Overview
Epix Pharmaceuticals developed small molecule drugs targeting serotonin receptors for CNS disorders and pulmonary hypertension. Its lead assets included PRX‑00023 for depression/anxiety, PRX‑03140 for Alzheimer’s disease, PRX‑07034 for obesity/cognitive impairment, and PRX‑08066 for pulmonary hypertension. The company entered liquidation in mid‑2009 due to lack of funds.
- Therapeutic areas
- PulmonologyPsychiatryImmunologyEndocrinologyNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
Amgen ($300M deal pre-merger)
Beyond the preview
Go deeper on Epix Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epix Pharmaceuticals.